863971-53-3
Chemical Structure
Fmoc-Val-Cit-PAB-PNP
- No. CAS: 863971-53-3
- Formula:C40H42N6O10
- Molecular Weight:766.80
IUPAC Name: (9H-fluoren-9-yl)methyl ((S)-3-methyl-1-(((S)-1-((4-((((4-nitrophenoxy)carbonyl)oxy)methyl)phenyl)amino)-1-oxo-5-ureidopentan-2-yl)amino)-1-oxobutan-2-yl)carbamate
InChIKey: USMYACISHVPTHK-PXLJZGITSA-N
SMILES: CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(COC(OC2=CC=C([N+]([O-])=O)C=C2)=O)C=C1)=O)=O)NC(OCC3C4=C(C5=C3C=CC=C5)C=CC=C4)=O
Biological Activity: Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers[1][2][3].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fmoc-Val-Cit-PAB-PNP | 99.60% | Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.89
HY-176930N-Fmoc-EvcPAB-PNP -
Similarity Score 0.88
HY-W591440Fmoc-Cit-PAB-PNP -
Similarity Score 0.87
HY-136136Fmoc-Val-Ala-PAB-PNP -
Similarity Score 0.86
HY-136108Fmoc-Gly3-Val-Cit-PAB-PNP -
Similarity Score 0.84
HY-129361Fmoc-Ala-Ala-Asn-PABC-PNP -
Similarity Score 0.81
HY-W591439Fmoc-Lys(Boc)-PAB-PNP -
Similarity Score 0.80
HY-144628Fmoc-Asn-Pro-Val-PABC-PNP -
Similarity Score 0.77
HY-W591441Fmoc-Ala-PAB-PNP -
Similarity Score 0.77
HY-114430Fmoc-Phe-Lys(Boc)-PAB-PNP -
Explore the MedChemAI to find more analogs
References
- [1]. Dubowchik GM, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem. 2002 Jul-Aug;13(4):855-69. [Content Brief]
- [2]. Yoneda Y, et al. A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. Bioorg Med Chem Lett. 2008 Mar 1;18(5):1632-6. [Content Brief]
- [3]. Dorywalska M, et al. Effect of attachment site on stability of cleavable antibody drug conjugates. Bioconjug Chem. 2015 Apr 15;26(4):650-9. [Content Brief]
